12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02320318 | Withdrawn Phase 3

• 1 other identifier: NAK-08
• Study Type: interventional
• Target: N/A
• Locations: 3 countries
• Sites: 20

Brief Summary

Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea. The aim of this trial is the evaluation of the efficacy and safety of oral ibodutant 10 mg once daily as compared to placebo in women with IBS-D over a 12-week treatment period.

Conditions

Irritable Bowel Syndrome With Diarrhea

Keywords

Irritable Bowel Syndrome; Colon, irritable; Bowel disease; Diarrhea

Outcome Measures

Primary Outcomes (1)

• Weekly response for abdominal pain intensity AND stool consistency over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).

  The patient will be considered a weekly responder if she meets both of the following criteria in the same week: * Abdominal pain response: decrease in weekly average of worst abdominal pain score in the past 24 hours of at least 30% compared with baseline; * Stool consistency response: decrease of at least 50% in the number of days per week with at least one stool that has a consistency of Type 6 or 7 compared with baseline.

  12-week

Secondary Outcomes (4)

• Weekly response for abdominal pain intensity over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).

  12-week

• Weekly response for stool consistency over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).

  12-week

• Weekly Response for relief of overall IBS signs and symptoms over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).

  12-week

• Evaluation of rebound effects

  12-week

Study Arms (2)

Ibodutant 10 mg

EXPERIMENTAL

Oral tablet once daily for 12 weeks of treatment. At week 13, patients in the ibodutant 10 mg arm will be re-randomised in a 1:1 ratio to either ibodutant 10 mg or placebo for additional 4 weeks of treatment.

Drug: Ibodutant 10 mg

Placebo

PLACEBO COMPARATOR

Oral tablet once daily for 12 weeks of treatment. At week 13, patients in the placebo arm will be mock-re-randomised (switch in blinded conditions) to ibodutant 10 mg for additional 4 weeks of treatment.

Drug: Placebo

Interventions

Ibodutant 10 mg DRUG

Oral tablet, once daily.

Also known as: MEN 15596

Ibodutant 10 mg

Placebo DRUG

Oral tablet (identical in appearance and weight to ibodutant tablet), once daily.

Also known as: Sugar pill

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Female patients aged 18 years or older.
• Belonging to the Asian race and specifically to the Chinese, Indian and Korean ethnicity.
• Clinical diagnosis of IBS-D according to the following symptoms, based on Rome III modular questionnaire criteria:
• Recurrent abdominal pain or discomfort for at least 3 days per month in the last 3 months associated with at least 2 of the following characteristics:
• improvement with defecation
• onset associated with a change in the frequency of stool
• onset associated with a change in form (appearance) of stool.
• Symptom-onset at least 6 months prior to diagnosis.
• Loose or watery stools at least 25% of the time in the last 3 months AND hard or lumpy stools less than 25% of the time in the last 3 months.
• Additional criterion: More than 3 bowel movements per day at least 25% of the time in the last 3 months.
• For patients older than 50 years OR patients with a positive family history of colorectal cancer: Normal results from colonoscopy/flexible sigmoidoscopy performed within the last 5 years.
• For patients aged 65 years or older: Absence of ischaemic colitis, microscopy colitis or any other organic gastrointestinal disease as evidenced by the results of a colonoscopy/flexible sigmoidoscopy with biopsy performed within 6 months.
• For women of childbearing potential: Use of a highly effective contraceptive method with a failure rate \<1% per year throughout the entire study period.
• Physical examination without clinically relevant abnormalities during screening.
• No clinically relevant abnormalities in 12-Lead ECG or in laboratory findings.

You may not qualify if:

• Male gender.
• Diagnosis of IBS with a subtype of constipation, mixed IBS, or un-subtyped IBS.
• Colonic or major abdominal surgery, any other major abdominal surgery or elective major surgery planned or expected during the study.
• History of organic GI abnormalities, inflammatory bowel diseases, complicated diverticulosis, ischaemic colitis, microscopic colitis.
• History of pancreatitis, active biliary duct disease, cholecystitis or symptomatic gallbladder stone disease in the previous 6 months.
• History of gluten enteropathy or lactose intolerance.
• Current or previous diagnosis of neoplasia.
• History of endometriosis.
• History of positive tests for ova or parasites, or clostridium difficile toxin or occult blood in the stool in the previous 6 months.
• History of human immunodeficiency virus infection.
• History of major cardiovascular events in the previous 6 months.
• Uncontrolled hypertension, insulin-dependent diabetes mellitus or abnormal thyroid function.
• Major psychiatric or neurological disorders or unstable medical condition which may compromise the efficacy and safety assessments.
• Evidence of clinically significant hepatic disease, severe renal insufficiency or anemia.
• Relevant changes in dietary habits, lifestyle, or exercise regimen in the previous 2 months.

Sponsors & Collaborators

• Menarini Group: lead

Study Sites (20)

Unknown Facility

Singapore, 258500, Singapore

Location

Unknown Facility

Singapore, 308433, Singapore

Location

Unknown Facility

Singapore, 529889, Singapore

Location

Unknown Facility

Busan, 602739, South Korea

Location

Unknown Facility

Daegu, 705718, South Korea

Location

Unknown Facility

Gangwon-do, 200704, South Korea

Location

Unknown Facility

Gyeonggi-do, 463712, South Korea

Location

Unknown Facility

Gyeonggi-do, 471701, South Korea

Location

Unknown Facility

Seoul, 110744, South Korea

Location

Unknown Facility

Seoul, 137701, South Korea

Location

Unknown Facility

Seoul, 138736, South Korea

Location

Unknown Facility

Kaohsiung City, 807, Taiwan

Location

Unknown Facility

Kaohsiung City, 83301, Taiwan

Location

Unknown Facility

Taichung, 40201, Taiwan

Location

Unknown Facility

Tainan, 704, Taiwan

Location

Unknown Facility

Taipei, 10002, Taiwan

Location

Unknown Facility

Taipei, 104, Taiwan

Location

Unknown Facility

Taipei, 11217, Taiwan

Location

Unknown Facility

Taoyuan District, 333, Taiwan

Location

Unknown Facility

Yunlin, 640, Taiwan

Location

MeSH Terms

Conditions

Irritable Bowel Syndrome; Intestinal Diseases; Diarrhea

Interventions

ibodutant; 6-methylbenzo(b)thiophene-2-carboxylic acid (1-(2-phenyl-((1-(tetrahydropyran-4-ylmethyl)piperidin-4-ylmethyl)carbamoyl)ethylcarbamoyl)cyclophenyl)amide; Sugars

Condition Hierarchy (Ancestors)

Colonic Diseases, Functional; Colonic Diseases; Gastrointestinal Diseases; Digestive System Diseases; Signs and Symptoms, Digestive; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Carbohydrates

Study Officials

• Jan F Tack, Prof.

  Department of Gastroenterology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 12, 2014
• First Posted: December 19, 2014
• Study Start: October 1, 2015
• Primary Completion: December 1, 2016
• Study Completion: December 1, 2016
• Last Updated: May 19, 2016

Record last verified: 2016-05

Locations

TW (9); KR (8); SG (3)